Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Life Sci. 2005 Nov 12;77(26):3259-67. Epub 2005 Jun 23.

New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.

Author information

  • 1CNR Institute of Neuroscience-Cagliari section, Italy. apinna@unica.it

Abstract

The development of non-dopaminergic therapies for the treatment of Parkinson's disease (PD) has attracted much interest in recent years. Among new different classes of drugs, adenosine A2A receptor antagonists have emerged as best candidates. The present review will provide an updated summary of the results reported in literature concerning the effects of adenosine A2A antagonists in rodent and primate models of PD. These results show that A2A receptor antagonists improve motor deficits without inducing dyskinesia and counteract parkinsonian tremor. In progress clinical trials have shown that a low dose of L-DOPA plus KW-6002 produced symptomatic relief no different from that produced by an optimal dose of L-DOPA alone, whereas dyskinesias were reduced rendering this class of compounds particularly attractive.

PMID:
15979104
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk